Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae
Authors:
- Céline ChauleurCCCéline Chauleur
- Jean-Luc FaillieJFJean-Luc Faillie
- Guillaume BaerGBGuillaume Baer
- Pierre MarèsPMPierre Marès
- Pascale Fabbro-PerayPFPascale Fabbro-Peray
- Isabelle QuéréIQIsabelle Quéré
- Jean-Yves LefrantJLJean-Yves Lefrant
- Bassam HaddadBHBassam Haddad
- Michel DauzatMDMichel Dauzat
- Jean-Christophe GrisJean-Christophe Gris
- 1 January 2010
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 104 (10) , 771-779
Abstract
Summary: Administration of heparin in the secondary prevention of placental vascular complications is still experimental. In women with a previous placental abruption, we investigated the effectiveness of enoxaparin, a low-molecular-weight heparin, in preventing these complications. Between January 2000 and January 2009, 160 women from the NOHA First cohort, with previous abruptio placentae but no foetal loss during their first pregnancy and negative for antiphospholipid antibodies, were randomised to either a prophylactic daily dose of enoxaparin starting from the positive pregnancy test (n=80), or no enoxaparin (n=80). The primary outcome was a composite of at least one of the following: abruptio placentae, preeclampsia, birthweight < 5th percentile, or foetal loss after 20 weeks. Enoxaparin was associated with a lower frequency of primary outcome: 12.5% (n=10/80) vs. 31.3 % (25/80), p=0.004, adjusted hazard ratio = 0.37, 95% confidence interval (0.18–0.77), p=0.011. Enoxaparin was safe, with no obvious side-effect, no thrombocytopenia nor major bleeding event excess. This pilot study shows that enoxaparin given early during the second pregnancy decreases the occurrence of placental vascular complications in women with a previous placental abruption during their first pregnancy.Keywords
This publication has 11 references indexed in Scilit:
- Heparin and maternal fetal interface: Why should it work to prevent pregnancy complications?Thrombosis Research, 2009
- Occurrence of placental abruption in relativesBJOG: An International Journal of Obstetrics & Gynaecology, 2009
- Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trialJournal of Thrombosis and Haemostasis, 2009
- Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and PregnancyChest, 2008
- Influence of Maternal Smoking on Placental Abruption in Successive Pregnancies: A Population-based Prospective Cohort Study in SwedenAmerican Journal of Epidemiology, 2007
- Antiplatelet agents for preventing pre-eclampsia and its complicationsCochrane Database of Systematic Reviews, 2007
- French fetal biometry: reference equations and comparison with other chartsUltrasound in Obstetrics & Gynecology, 2006
- Thrombophilia in pregnancy: a systematic reviewBritish Journal of Haematology, 2005
- Low-Molecular-Weight Heparin Lowers the Recurrence Rate of Preeclampsia and Restores the Physiological Vascular Changes in Angiotensin-Converting Enzyme DD WomenHypertension, 2005
- Clinical management of thrombophilia-related placental vascular complicationsBlood, 2004